Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/MTA nucleosidase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 12, 2004, Pages 3165-3168

  Tedder, Martina E ^a   Nie, Zhe ^a   Margosiak, Stephen ^a   Chu, Shaosong ^a   Feher, Victoria A ^a   Almassy, Robert ^a   Appelt, Krzysztof ^a   Yager, Kraig M ^a  

^a Quorex Pharmaceuticals   (United States)

Author keywords

Antimicrobial; Structure based drug design

Indexed keywords

ADENOSYLHOMOCYSTEINASE INHIBITOR; ANTIBIOTIC AGENT; PURINE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; INHIBITION KINETICS; SUBSTITUTION REACTION;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HOMOCYSTEINE; N-GLYCOSYL HYDROLASES; PURINE-NUCLEOSIDE PHOSPHORYLASE; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2442583105     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.04.006     Document Type: Article

References (25)

1. Projan S.J. Current Opinion Pharmacol. 2:2002;513-522
2. Viable pfs-null mutants of Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus could not be generated. The pfs gene is not essential in Enterococcus faecalis and may therefore not be essential in other Gram-positive strains where efflux pumps may be upregulated. Grant, C. and Levin, J., Quorex Pharmaceuticals, unpublished results
3. Mao C., Cook W.J., Zhou M., Federov A.A., Almo S.C., Ealick S.E. Biochemistry. 37:1998;7135-7146
4. Koellner G., Luic M., Shugar D., Saenger W., Bzowska A. J. Mol. Biol. 280:1998;153-166
5. Li X., Chu S., Feher V.A., Khalili M., Nie Z., Margosiak S., Nikulin V., Sprankle K.G., Tedder M.E., Almassy R., Levin J., Appelt K., Yager K.M. J. Med. Chem. 46:2003;5663-5673
6. Della Ragione F., Porcelli M., Carteni-Farina M., Zappia V., Pegg A.E. Biochem. J. 232:1985;335-341
7. Cornell K.A., Swarts W.E., Barry R.D., Riscoe M.K. Biochem. Biophys. Res. Comm. 228:1996;724-732
8. Allart B., Gatel M., Guillerm D., Guillerm G. Eur. J. Biochem. 256:1998;155-162
9. Cornell K.A., Riscoe M.K. Biochim. Biophys. Acta. 1396:1998;8-14
10. Lee J.E., Cornell K.A., Riscoe M.K., Howell P.L. Structure. 9:2001;941-953
11. Lee J.E., Corrnell K.A., Riscoe M.K., Howell P.L. J. Biol. Chem. 278:2003;8761-8770
12. Surette M.G., Miller M.B., Bassler B.L. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1639-1644
13. Schauder S., Shokat K., Surette M.G., Bassler B.L. Mol. Biol. 41:2001;463-476
14. Details of the enzymatic assays used in this study may be found in Ref. 5
15. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.F. Adv. Drug Delivery Rev. 1997;23
16. Unity and Selector software Tripos, Inc. St. Louis, MO
17. Sheridan R.P., Nachbar R.B., Bush B.L. J. Comp-Aided Mol. Des. 8:1994;323-340
18. Seyama F., Akahori K., Sakata Y., Misumi S., Aida M., Nagata C. J. Am. Chem. Soc. 110:1988;2192-2201
19. Jacobsen K.A., Siddiqi S.M., Olah M.E., Ji X.-D., Melman N., Bellamkonda K., Meshulam Y., Stiles G.L., Kim H.O. J. Med. Chem. 38:1995;1720-1735
20. Baker B.F., Dervan P.B. J. Am. Chem. Soc. 111:1989;2700-2712
21. Shadid B., van der Plas H.C., Boesten W.H.J., Kamphuis J., Meijer E.M., Schoemaker H.E. Tetrahedron. 46:1990;913-920
22. Itoh T., Ono K., Sugawara T., Mizuno Y. J. Heterocycl. Chem. 19:1982;513-517
23. MTA nucleosidase crystallizes with two molecules per asymmetric unit. Periodically, small differences in side-chain and inhibitor conformations were observed between subunits
24. Palanki M.S., Erdman P.E., Manning A.M., Ow A., Ransone L.J., Spooner C., Suto C., Suto M. Bioorg. Med. Chem. Lett. 10:2000;1645-1648
25. Minimum inhibitory concentration (MIC) values were typically ≥30 μM (∼12 μg/mL)